Cargando…

Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer

Multi-kinase inhibitors (MKIs) represent the best therapeutic option in advanced thyroid cancer patients. The therapeutic efficacy and toxicity of MKIs are very heterogeneous and are difficult to predict before starting treatment. Moreover, due to the development of severe adverse events, it is nece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cantara, Silvia, Dalmiglio, Cristina, Marzocchi, Carlotta, Sagnella, Alfonso, Brilli, Lucia, Trimarchi, Andrea, Maino, Fabio, Valerio, Laura, Castagna, Maria Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049548/ https://www.ncbi.nlm.nih.gov/pubmed/36982571 http://dx.doi.org/10.3390/ijms24065496

Ejemplares similares

PAPPA Expression in Indeterminate Thyroid Nodules as Screening Test to Select Patients for Molecular Testing
por: Marzocchi, Carlotta, et al.
Publicado: (2022)

Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients
por: Capezzone, Marco, et al.
Publicado: (2022)

Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a novel missense mutation in AVP gene in a large Italian kindred
por: Marzocchi, Carlotta, et al.
Publicado: (2021)

The Combination of Sonographic Features and the Seven-Gene Panel May be Useful in the Management of Thyroid Nodules With Indeterminate Cytology
por: Capezzone, Marco, et al.
Publicado: (2021)

Dynamic Risk Stratification Integrated with ATA Risk System for Predicting Long-Term Outcome in Papillary Thyroid Cancer
por: Valerio, Laura, et al.
Publicado: (2023)

Effect of Pre-Existent Sarcopenia on Oncological Outcome of Advanced Thyroid Cancer Patients Treated with Tyrosine Kinase Inhibitors
por: Dalmiglio, Cristina, et al.
Publicado: (2022)

Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience
por: Brilli, Lucia, et al.
Publicado: (2021)

From Circulating Tumor Cells to Mirna: New Challenges in the Diagnosis and Prognosis of Medullary Thyroid Cancer
por: Ricci, Claudia, et al.
Publicado: (2023)

EIF1AX c.338-2A>T splice site mutation in a patient with trabecular adenoma and cytological indeterminate lesion
por: Castagna, Maria Grazia, et al.
Publicado: (2020)

CONUT Score: A New Tool for Predicting Prognosis in Patients with Advanced Thyroid Cancer Treated with TKI
por: Dalmiglio, Cristina, et al.
Publicado: (2022)

Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a “surgical” and a “cytological” series
por: Marzocchi, C., et al.
Publicado: (2021)

Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis
por: Cantara, Silvia, et al.
Publicado: (2017)

Alteration of Serum Proteome in Levo-Thyroxine-Euthyroid Thyroidectomized Patients
por: Landi, Claudia, et al.
Publicado: (2022)

Editorial: Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Clinical and Genetic Update
por: Valerio, Laura, et al.
Publicado: (2022)

Silent thyroiditis following vaccination against COVID-19: report of two cases
por: Capezzone, M., et al.
Publicado: (2022)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Type 2 deiodinase p.Thr92Ala polymorphism does not affect the severity of obesity and weight loss after bariatric surgery
por: Benenati, Nicoletta, et al.
Publicado: (2022)

Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event
por: Monti, Salvatore, et al.
Publicado: (2022)

Familial non-medullary thyroid cancer: a critical review
por: Capezzone, M., et al.
Publicado: (2020)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Nodular Thyroid Disease in the Era of Precision Medicine
por: Tumino, Dario, et al.
Publicado: (2020)

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
por: Hamidi, Sarah, et al.
Publicado: (2022)

miRNA Targets: From Prediction Tools to Experimental Validation
por: Riolo, Giulia, et al.
Publicado: (2020)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
por: Oishi, Kazuyuki, et al.
Publicado: (2017)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
por: Roque, João, et al.
Publicado: (2023)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
por: Costa, Ricardo, et al.
Publicado: (2016)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020)

Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
por: Toda, Soji, et al.
Publicado: (2021)

Lenvatinib-Induced Destructive Thyroiditis in a Patient With Hepatocellular Carcinoma
por: Pandya, Anjani, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
por: Zafón, Carles, et al.
Publicado: (2022)

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers
por: Peelay, Zoya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c8atmlb246ks2m67p58c935lah